Abstract
Introduction
Ob stru cti ve slee p apnea sy ndro me (OSAS) can result in daytime fatigue and slee piness that sig nifica ntly affect s, and eve n threatens, the life of the patient. Tracheotomy was the first treatment for OSAS. It bypasse s all forms of obstructio n in the upp er airway, thu s eliminating the di sea se. However , the morbidity assoc iated with tracheoto my prevents its use in mo st patients.
Sullivan et al first reported the application of nasal continuous po sitive airway pressur e (CPAP) to maintain upp er airway pat enc y for OSAS .' Becau se of its effe ctiveness, na sal CPAP is curre ntly the first-line tre atm ent for OSAS. However, patient co mpliance remains a major probl em, and the lon g-term use of C PA P is likely to be an unr eal isti c ex pectatio n in man y cases."! In 197 9, Fujita et al rep ort ed the initi al res ults of uv ulopal atophar yn gopl asty in the treatment of OSAS. 5 Althou gh the pro cedure has pro ved to be an ex ce lle nt method of allev iating palat al (p haryngeal) airway obstruc tio n, the untreated base-of-ton gu e (hy po pharyngeal) obs truc tio n resul ted in only ap proxi ma tely 40 % of patient s res po ndi ng to treatment."
Recognizing that multiple level s of upp er airway obstruc tio n exist in OS AS , we develop ed se veral proce-du res to ta rge t the specific ana to mic reg ion s invol ved . Our two-phase surgi ca l prot ocol was design ed to alleviate the anato mic obstruc tion(s) whi le min im izing surg ica l interventi on s and avoidi ng unn ecessary surge ry. The ph ase I surgical prot ocol addresses obs tructions at the nasal , pal atal , and base-of-tongu e level s. Ph ase I procedures include nasal recon stru cti on , uvu lop alat oph aryng oplasty , mandibu lar os teo tomy with ge niog lossus adva nce ment, and hyo id myotomy and sus pe ns ion. In 1992, we re ported a cure rat e of 61 % foll owin g phase I surgery.' Depending on the severity of OS AS, the success rat e of ph ase I surge ry ran ge s from 42 to 78 % .7 Cl early, man y pat ients co nti nue to experience persi stent dise ase following phase I surgery, and most of them become candidates for phase II surge ry. Ph ase II surge ry consi sts of maxillomandibular advancement, a procedure that was fir st described for the treatment of craniomaxill ofacial deformity.
Rationale for maxillomandibular advancement
Th e contributing cau ses that lead to OSAS are mu ltifactori al, and they can have a negat ive influence on the del icate balance necessary fo r airway patency during slee p. In additio n to ob esit y, male ge nde r, age, and ethnicity, " !? cra nio max illofacia l abnor ma lity is a wellrecognized predi ct or of OS AS. I 1·13 Man y of these pati ents have a maxillom andibular deficien cy that res ults in a dimini sh ed airway dim en sion and lead s to nocturnal obstruc tio n. In 1983, we re po rted that maxill o fac ial surgery via mandibular advance me nt ca n play a rol e in the treatme nt of OSAS .
14 Mandibular mo vem ent forward will help in alle viatin g a hypopharyn geal obs truction. This finding has also been recognized by others.":" In fact, it was repo rted that mandibular se tbac k fo r the correction of mandibu lar pro gn athi sm ha s produced OSAS. 18 We subse quently investi gated the effect o f maxi llomandib ular advancement on the airway and ha ve incl uded this proce - dur e as the second pha se of our surg ica l protocol." Ma xillomandibul ar ad vancem ent enlarges the pharyngeal and hypopharyn geal air way dimensions by physically expanding the skeletal fram ework. In addition, the forw ard mov em ent of the ma xillomandibular co mplex improves the ten sion and collapsib ilit y of the suprahyoid and velophary ngeal musculature. The indications for max illom andibular adv anceme nt are outlined in tabl e I.
Mo st patients who undergo pha se II surgery have failed to fully respond to the pha se I prot oco\' These pati ent s have alread y und ergo ne reconstru cti on of the air way at the nas al, pharyngeal , and hypopharyngeallevels. Pha se I surg ica l failure alm ost always invo lves persistent obstruction at the hyp oph aryn geallevel (occas ionally combin ed with ph aryngeal-l evel obstruction) . Ma xillornandibular advance me nt crea tes more ten sion and physical room in the upp er airwa y, relie ving residual obstruc tions. In order to maximi ze airway expansion , a major adva ncement ofthe ma xillomand ibularcomplex is required . However, in doing so, it is important to maint ain a stable dental occlusion and a balan ced aesthetic appea rance. Many pati ents w ho e n te r the phas e II proto col h a ve crani om axillo faci al abnormalities, such as maxillary and/ or mandibular deficien cies, that invar iabl y are imp roved following surge ry . We have often fo und that eve n patient s whos e cephalometric measurem ent s are norm al also experien ce an improv em ent in their fac ial app earance followin g maxillomandibular ad vancement. Th is is becau se many of our pati ent s are middl e-aged adults who are already showing signs of fac ial ag ing as a result of soft tissue sagging . Th e skeletal expan sion of the maxilla and mandible enh anc es their appearance by imp rovin g soft tissue supp ort. Thi s positive influ en ce on aesthetics has been reported by others .P:"
Surgical procedure
Maxillomandibular adva nceme nt has been perform ed for man y year s to correct malo cclu sion in children and young adults, and it is we ll describ ed in the maxill ofacial surge ry literature. How ever, it mu st be emphasized that the procedure for the treatm ent of OS AS is quite different from the convention al orthog nathic pro cedure.
Th e procedure begins with an out er- Rat Hepatocyte DNA Repai r Assay Mi cronucleusTest (Mice) Dominant LethalTe st (Mice) Long-term carci nogenicity studies in mice and rats have been completed for ciprofloxacin. After daily oral doses of 750 mg/kg (mice) and 250 mg/kg(rats) wereadministered for upto 2 years, there was no evi dence that ciprofloxacin had anycarcinogenic or tumori genic effects in these species. No long term studiesof CIPRO ' HC OTI Csuspension have been performedto evaluatecarcinogenicpotential. Fertility studiesperf ormed in rats at oral doses of ciprofloxacin upto 100 mg/kg/day reveal ed no evidence of impairment. Thi s would be over 1000times the maximum recommended clinical dose of ototopical ciprofloxacin baseduponbody surface area, assuming total absorption of ciprofloxacin from theear of a pat ient treatedwi th CIPRO' HCOTI Ctwice perday. Long term studieshave not been performed to evaluate thecarcinogenic potential or theeffect on fertiiity of topical hydrocortisone. Mut agenicity studieswith hydrocortisonewerenegative. Pregnancy: Teratogenic Effects. Pregnancy Category C: Reproductionstudies have beenperformed in rats and mi ce using oral doses of upto 100 mglkg and IV doses up to 30 mglkg and have reveal edno evidence of harm to the fetusasa resultof ciprofloxacin. ln rabbits,clpronoxacln(30 and 100 mglk g orally)prod ucedgastroi ntestinal disturbances resulting in maternal weight loss andan increased incidence of abortion, but no teratogenicity was observedat ei ther dose. After intravenousadministrat ionofdoses upto20mglkg,no maternal toxicity was produced in the rabbit, and no embryotoxicity or teratogenicity was observed. Corficosteroldsare generall y teratogeni c in iaboratory animalswhen administered systemicallyat relatively low dosage level s. The morepotent corticosteroids have been shown to beteratogenic afterdermalapplication in laboratory animals. Animal repr oducti onstudieshavenotbeen conductedwithCIPRO' HC OTIC. Noadequateandwell controlled studies havebeenperf ormed in pregnant women. Caution shoul d be exercised when CIPRO' HCOTIC is usedbya preg nant woman, Nursing Mothers: Ciprofloxacin is excretedin humanmilk with systemicuse. It is not known whet her ciprofloxacin is excrete d in humanmilk foll owing topi cal otic administration. Because of the potential for serious adverse reactio ns in nursing infants,a decision should be made whether to discontinue nursing or to discontinuethedrug, takingintoaccount the importance of thedrug to the mother. Pediatric use: The safety and efficacy of CIPRO ' HC OTIChave beenestablished in pediatric pati ents 2 years and older (131 pati ents) in adequate and well-controlled cli nical trials. Al though no data areavailableon patients less thanage 2years,thereareno knownsafetyconcerns or differences inthe disease process inthis populati onwhich would preclude useof this product in patients oneyear and older. See DOSAGE AND ADMINISTRATION. ADVERSE REACTIONS InPhase3clinical trials, atotalof 564 patientswere treatedwi thCIPRO' HCOTIC. Adverse events withat least remoterel ationship to treatment included headache(1.2%) andpruritus (0.4%). Th e foll owing treatment-related adverse events were each reported in a single patient: mi graine, hypesthesia, paresthesia, fungal der matitis, cough, rash, urti caria, and alopecia. NDC0065-8531-10 CIPRO' is a registeredtrademark of BayerAG. OVERVIEW OF PHASE II SURG ERY FOR OB STRU CTIVE SLEEP APNE A SYNDROME facilitate bony union. To maintain dental occlu sion , either arc h bars or orthodont ic band s are requi red pri or to osteotomy. A Le Fort I ma xillary osteot omy (figure) is performed above the apices of the teeth . Th e ma xilla is down-fractured after pterygom axill ary separation . The de scending palatine art erie s are ident ified and preserved . The mobilized maxilla is manipulated and advanced appro xim ately 10 mm . Alignment of the maxill a in relation to the mand ible , dentition, and the face is cruc ial to ensure acceptable occlusion and aesthetics . The maxilla is stabilized by rigid fixation with four plate s, and the cranial bone grafts are used in the osteotomy sites.
Mandibular osteoto my is performed via the sagi ttal split technique. The med ial and lateral cortex of the mandible are separated at the ramu s region, whil e the inferior alveolar ner ve is pre ser ved . Th e dentated mandibular seg ment is advanced the same distance as the maxilla, and occlu sion is restored. After the mandible is stabilized by intermaxill ary fixa tion, rigid fixation is achieved with the placement of four positional scre ws (plates are also occ asion ally used to ensure rigidi ty) .
We routinely use a prefab ricated methylmeth acrylate splint to en sure dental ali gnm ent. Skel etal fix ati on with suspension wir es is sometimes used to enhance the stabiliz ation of the maxillomandibular complex . Volume 78, Number 11
Perioperative management As alw ays, anesthesia indu ction and intubation are es peciall y critical for OSAS patient s, and the surgeons sho uld be present at all tim es. A fiberopti c intub ation or tracheotomy whil e the patient is awa ke should be considered in difficult airway situatio ns, especially in obese pati ent s who have a large neck circumference (>46 cm) and asso ciated ske letal deformities (e.g ., mand ibular deficiency and a low hyoid bon e). Altho ugh blood tran sfusion is oft en unn ecessar y, we prefer to have two unit s of autologo us blood available. All patients are extubated whil e they are awake, and inter max illa ry fixatio n is in place in the operating room imm edi ately follow ing surge ry. W ire cutte rs are kept nea r the se patient s at all time s. All patient s are monit ored via an arterial line in the intensive ca re un it dur ing the first po stope rati ve da y. Eithe r humidified ox ygen (35%) throu gh a face tent or nasal CP AP is admini stered throu ghout hospitali zation. Patients who receive CPAP requ ire nasal trumpets to prevent subcutaneo us emphyse ma. Patients are tran sferred to the ward the foll owing day . Disch arge criteria include a stable airwa y, adequate oral intake of flu ids, and satisfac tory pain control. Intermaxillary fixation is left in place fo r several days.
Surgical protocol clinical outcomes
Of the 175 patients who underwent phase II reconstruction at our institution between 1988 and 1995, 166 (95%) had a successful outco me (table 2) . Th eir mean respiratory disturbance index (RDI) was 72 .3 before surgery and 7.2 afterwa rd. Postsur gical RDI values were comparable with those for nasal CPAP (nasal CPAP RDI : 8.2;p=NS [not statistically significant]). Th e mean low est oxygenation saturation (LSAT) level improved from 64 to 86.7% (nasal CPAP LSAT : 87 .5%; p=NS). Eighty-six of these pati ent s had failed our phase I surgical prot ocol, and 83 of them (97%) were cured with pha se II sur gery. Most of the patient s who failed the pha se I prot ocol and declined pha se II surgery were older (mean age: 51.8 yr). The mean age of patients who underwent phase II treatment was 43.5 years. For mor e information Circle 111 o n Read er Service C ard
Oto vent ca n p rev e nt o r tr eat Otitis m edi a a nd ca n be an a lte rna t ive t o su rge ry.
The mean length of hospital stay after phase II surger y was 2.4 days. Surgical morbidity included transient anesthesia of the lower lip, chin , and cheek in all patients; 87% of these cases resolved in 6 to 12 month s. There was no postoperative bleeding or infection. Mild malocclusions were seen in some patients, and they were treated adequately with occlusal adj ustment. No major skeletal relapse has been reported.
To date, we have performed long-term followup on more than 50 patient s who underwent pha se II surgery. Thi rty-three of these patients have undergone followup polysomnography (table 3) . Eighte en pati ents who refused polysomnograph y are monitored throu gh interviews that concern the subjective symptoms of OSAS. Four patient s have been lost to followup.
Of the 33 pati ents who underwent followup polysomnography, 30 have experienced long-term surgical success; the other thre e patient s had initial success, only to relapse to OSAS . Overall, the mean RDI in this group fell from 69.6 preoperatively to 8.9 at 6 month s postoperatively and to 7.7 at long-term followup, Simil ar impro vement over baselin e was seen in 6-month and long-term LSAT values. Foll owup ranged from 12 to 110 month s (mean: 39).
Of the 18 patients who were subjectively reviewed by the lead author, 16 continued to experience good subje ctive correction. They had no progressive snoring, no apnea, and no excess ive daytime sleepiness . Of the two patients who did not improve, one experienced a subje ctive failure (rec urrence of snoring and daytime fatigue) and the other had both a subje ctive and obje ctive failure (his primary care phy sician had referred him for a polysomn ogram , whi ch showed a recurrence of OSAS ).
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